Abstract

BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and HRQOL in a well-documented clinical cohort during their last two years of life.MethodsIn April 2015, we sent the Modified Medical Research Council Dyspnea Scale (MMRC), the modified Edmonton Symptom Assessment Scale (ESAS) and a self-rating HRQOL questionnaire (RAND-36) to 300 IPF patients, of which 247 (82%) responded. Thereafter, follow-up questionnaires were sent every six months for two years.ResultsNinety-two patients died by August 2017. Among these patients, HRQOL was found to be considerably low already two years before death. The most prominent declines in HRQOL occurred in physical function, vitality, emotional role and social functioning (p < 0.001). The proportion of patients with MMRC scores ≥3 increased near death. Breathlessness and fatigue were the most severe symptoms. Symptom severity for the following symptoms increased significantly and reached the highest mean scores during the last six months of life (numeric rating scale/standard deviation): breathlessness (7.1/2.8), tiredness (7.0/2.3), dry mouth (6.0/3.0), cough (5.8/2.9), and pain with movement (5.0/3.5).ConclusionsTo our knowledge this is the first study demonstrating, that IPF patients experience remarkably low HRQOL already two years before death, especially regarding physical role. In addition, they suffer from severe breathlessness and fatigue. Furthermore, physical, social and emotional wellbeing deteriorate, and symptom burden increases near death. Regular symptom and HRQOL measurements are essential to assess palliative care needs in patients with IPF.

Highlights

  • Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL)

  • This study aimed to investigate IPF patients’ HRQOL and symptom burden during the last two years of life in a prospective longitudinal follow-up study to recognise needs for palliative care and end-of-life care planning and to characterise their symptom burden in a unique follow-up setting

  • Patients from these specialist centres with informed consent are included in the FinnishIPF registry, which consists of approximately 76% of all Finnish IPF patients [2]

Read more

Summary

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). Idiopathic pulmonary fibrosis (IPF) is a chronic disease with high morbidity and poor survival [1,2,3,4]. The disease trajectory of IPF is variable, for many patients with IPF, survival is worse than many common malignancies This necessitates early integration of palliative care to improve patients’ quality of life (QOL) and to relieve symptoms in addition to disease-specific pharmacological treatment and lung transplant assessment [5,6,7,8,9]. IPF patients have been shown to suffer from lower HRQOL in real-life studies than in clinical studies [12, 13]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call